Document is current
Any future updates will be listed below
-
Authors
Botsch, J. Josephine https://orcid.org/0000-0002-3358-7069
Junker, Roswitha https://orcid.org/0009-0007-9355-5855
Sorgenfrei, Michèle https://orcid.org/0000-0001-8480-197X
Ogger, Patricia P. https://orcid.org/0000-0002-2698-3565
Stier, Luca
von Gronau, Susanne
Murray, Peter J. https://orcid.org/0000-0001-6329-9802
Seeger, Markus A. https://orcid.org/0000-0003-1761-8571
Schulman, Brenda A. https://orcid.org/0000-0002-3083-1126
Bräuning, Bastian https://orcid.org/0000-0002-7194-2500
- License Information
-
More Information
Article History
Received: 12 June 2023
Accepted: 19 December 2023
First Online: 9 January 2024
Competing interests
: B.A.S. is adjunct faculty at St. Jude Children’s Research Hospital, Memphis, TN, USA, is on the Scientific Advisory Boards of BioTheryX and Proxygen, and is co-inventor of intellectual property related to DCN1 inhibitors (unrelated to this work) licensed to Cinsano. M.A.S. is co-founder and shareholder of Linkster Therapeutics AG. The remaining authors declare no competing interest.
